The cardiovascular outcomes trials with the SGLT2 inhibitors canagliflozin and empagliflozin do not provide data on the forms of HF and HF‐related events being prevented, with a small percentage of patients having HF at baseline. This evidence concerns the gene SLC5A2 and hydrops fetalis.